The NHMRC has announced $29 million for medical research institute support services

It's been a big year for Starpharma, the Melbourne-based biotech working on a portfolio of applications for its dendrimer technology.

Melbourne company Invision IT says its Evado software overcomes EDC shortcomings.

The 2008 Pfizer Australia Research Fellowships have been announced, bringing one Australian scientist home.

A system able to deliver drugs straight to the heart of conscious patients has won a local award.

The Victorian delegation started BIO with a bang, announcing a slew of new initiatives.

Evolution is being harnessed for modern drug development by West Australian biotech Phylogica.

The first merger of 2006 has created new opportunities in the hot field of theranostics. Ruth Beran talks with its architects about the merged company and its future plans.

Biopharmaceutical company Novogen's (ASX:NRT) cardiovascular drug trans NV-04 has shown a significant reduction in blood pressure and reduced arterial stiffness in a Phase Ib clinical trial.

V-Kardia, the first spin-off company from the Baker Heart Research Institute in Melbourne, has entered into an agreement with Californian-based molecular cardiology company, Celladon, to develop and supply its V-Focus device for percutaneous delivery of gene therapy for congestive heart failure.

Two Melbourne researchers, Dr Merlin Thomas and Dr Stephen Ting, have jointly won the 2005 Victorian Premier's Award for Medical Research.